# China Vascular Embolization Market > China Vascular Embolization Market Research Report: Size, Share, Trend Analysis By Embolization Technique (Coiling Devices, Non-coiling Devices) andBy Applications (Peripheral Vascular Disease, Oncology, Neurology, Urology, Other) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 9.9% - **2024:** $ 208.81 Million - **2025:** $ 229.49 Million - **2035:** $ 590 Million - **Key Players:** Medtronic (US), Boston Scientific (US), Terumo (JP), Johnson & Johnson (US), Stryker (US), B. Braun (DE), Cook Medical (US), Abbott (US) **Report ID:** MRFR/HC/50302-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/china-vascular-embolization-market-52060 --- ## Market Summary ## **China Vascular Embolization Market Overview** As per MRFR analysis, the China Vascular Embolization Market Size was estimated at 142.63 (USD Million) in 2023. The China Vascular Embolization Market Industry is expected to grow from 156.75(USD Million) in 2024 to 424 (USD Million) by 2035. The China Vascular Embolization Market CAGR (growth rate) is expected to be around 9.468% during the forecast period (2025 - 2035). ### **Key China Vascular Embolization Market Trends Highlighted** In the China [Vascular Embolization Market](../../../reports/vascular-embolization-market-11872), there are significant trends that are being driven by a combination of factors that underscore the increasing significance of minimally invasive procedures. The ageing population in China, in conjunction with the growing prevalence of vascular diseases, is a substantial factor in the development of embolization techniques. Technologies that prioritize safety and efficacy are becoming increasingly prevalent as the healthcare system prioritizes the enhancement of patient outcomes and the reduction of recovery times.  The regulatory environment for the adoption of innovative products is being created by China's government initiatives, which are designed to improve healthcare infrastructure and promote the development of new medical technologies. There are numerous opportunities in the China Vascular Embolization Market, particularly for companies that can offer specialized solutions that are specifically designed to meet the unique requirements of Chinese patients. Manufacturers have the opportunity to introduce novel embolization materials and devices in response to the increasing demand for non-surgical treatment options. Additionally, partnerships with local firms can assist foreign companies in navigating the regulatory landscape and gaining a greater understanding of regional market dynamics, thereby extending their reach. The Vascular Embolization Market has experienced a recent trend of progressing towards the development of personalized medicine.  This trend is distinguished by the implementation of personalized treatment plans that are tailored to the unique requirements of each patient, thereby enhancing the efficacy of interventions.Additionally, the precision of procedures is being improved, resulting in improved clinical outcomes, as a result of the integration of sophisticated imaging technologies with embolization devices. The rapid advancements in the field of vascular embolization are expected to benefit an increasing number of patients in China as healthcare providers continue to implement such innovations. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ## **China Vascular Embolization Market Drivers** ### **Increasing Prevalence of Cancer in China** The incidence of cancer in China has seen a significant rise, which is a major driver for the China Vascular Embolization Market. According to the National Cancer Center of China, the estimated number of new cancer cases reached approximately 4.57 million in 2020, reflecting an increase of about 3.5% annually compared to the previous years. This growing burden of cancer is driving the demand for vascular embolization procedures, as they are effectively used to treat cancer-related conditions such as tumors by selectively blocking blood flow to the affected areas.With organizations like the Chinese Anti-Cancer Association actively promoting advancements in cancer treatment, the market for vascular embolization is expected to continue expanding to cater to this critical healthcare need. Furthermore, the Chinese government has been prioritizing cancer prevention and treatment in its healthcare reforms, further emphasizing the need for innovative solutions in the vascular embolization market. ### **Technological Advancements in Vascular Embolization Devices** The rapid advancement in medical technology, particularly in the field of vascular embolization devices, plays a crucial role in driving growth within the China Vascular Embolization Market Industry. Recent developments include the introduction of more effective embolic agents and delivery systems that enhance the precision and efficacy of the procedures. Notably, the Ministry of Science and Technology of China announced funding initiatives focused on the Research and Development of innovative medical devices.Such support has led to the emergence of next-generation embolization products that can significantly improve patient outcomes. With the increasing adoption of these technologically advanced devices by leading hospitals in major Chinese cities, there is a direct correlation to the anticipated growth of the vascular embolization market. ### **Growing Aging Population in China** China is witnessing a demographic shift with a rapidly increasing aging population, which is a significant driver for the China Vascular Embolization Market Industry. According to the National Bureau of Statistics of China, individuals aged 60 years and above are expected to reach over 300 million by 2040, which accounts for roughly 20% of the total population. This demographic shift will likely result in a higher occurrence of age-related health conditions that necessitate vascular embolization procedures, such as vascular malformations and cancers.The Chinese government's emphasis on improving healthcare access for older adults and the establishment of geriatric health initiatives have further highlighted the necessity for innovative treatment options in this sector. Thus, the intersection of an aging population and improved healthcare policies will contribute to a robust demand for vascular embolization procedures. ### **Government Initiatives to Improve Healthcare Infrastructure** The Chinese government is actively investing in and reforming its healthcare infrastructure, which directly benefits the China Vascular Embolization Market Industry. Recent initiatives include the Healthy China 2030 plan, an ambitious project aiming to enhance public health systems and increase the accessibility of advanced medical treatments across the nation. Funding allocated to hospitals and medical facilities is expected to increase significantly, allowing for the incorporation of state-of-the-art medical technology and trained personnel in vascular embolization procedures.According to official reports, this initiative is targeted to enhance healthcare access for millions of urban and rural residents, therefore increasing the adoption rate of vascular embolization techniques. Enhanced healthcare infrastructure can lead to not only increased treatment options but also better patient education and awareness about vascular embolization, ultimately contributing to market growth. ## **China Vascular Embolization Market Segment Insights:** ### **Vascular Embolization Market Embolization Technique Insights** The China Vascular Embolization Market encompasses a critical segment known as Embolization Technique, which plays a vital role in various medical treatments, particularly in addressing vascular conditions. This segment is experiencing significant growth due to the increasing prevalence of vascular diseases, which has resulted in a rising demand for effective intervention methods. Within this segment, the techniques can be broadly categorized into Coiling Devices and Non-coiling Devices.  Coiling Devices are particularly significant in the treatment of aneurysms, as they provide a minimally invasive option to prevent rupture by occluding the affected blood vessel.Their effectiveness and the benefits of reduced recovery times have contributed to their prominence within the China Vascular Embolization Market. On the other hand, Non-coiling Devices include a range of embolic agents such as gel foam, particulate agents, and other materials that are utilized in procedures aimed at controlling bleeding or inhibiting blood flow to tumors. These devices offer versatility in clinical applications, catering to a variety of patient needs and clinical scenarios. The demand for advanced embolization techniques is also being driven by an increasing number of trained healthcare professionals and greater access to modern medical facilities across China.Moreover, innovative technologies, particularly those enhancing the efficacy and safety of embolization procedures, are likely to further elevate the market dynamics. As healthcare stakeholders focus on improving patient outcomes, the Embolization Technique segment is set to expand, reflecting the ongoing advancements in medical technology and an overall trend towards optimizing vascular interventions. The growing awareness of vascular health and the need for timely interventions showcase the importance of this market segment in enhancing medical care in China. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ### **Vascular Embolization Market Application Insights** The Application segment of the China Vascular Embolization Market is characterized by diverse healthcare needs, contributing significantly to overall market dynamics. The increase in cases of Peripheral Vascular Disease has notably emphasized the importance of targeted embolization procedures, addressing critical issues related to blood flow and circulation. Similarly, the oncology sector has seen substantial adoption of embolization techniques to treat various malignancies, showcasing their efficacy in tumor reduction and management. Neurology applications hold importance as they provide solutions for conditions such as arteriovenous malformations.  At the same time, urology represents a growing field with procedures aimed at renal cancer and other conditions, enhancing therapeutic outcomes.Furthermore, other applications continue to innovate, embracing advancements in technology that lead to improved treatment options. The demand in these areas is heavily influenced by the increasing prevalence of chronic diseases and the aging population in China, fostering opportunities for healthcare providers and manufacturers. The evolving landscape of treatment protocols and the need for minimally invasive procedures further highlight the significance of this segment in driving the growth of the China Vascular Embolization Market. ## **China Vascular Embolization Market Key Players and Competitive Insights:** The China Vascular Embolization Market is characterized by a dynamic competitive landscape fueled by advancements in medical technology and an increasing prevalence of vascular diseases. This market has observed significant growth due to the rising demand for minimally invasive surgical procedures and the expansion of healthcare infrastructure across the country. Several factors, including the introduction of innovative products, strategic partnerships, and an increasing focus on research and development, shape the competitive landscape. Global and local players are vying for market share, each bringing unique products and services that cater to the needs of healthcare professionals and patients. The regulatory environment in China also influences market dynamics, as companies must navigate complex regulations to introduce their innovations effectively.CeloNova BioSciences has established a commendable position in the China Vascular Embolization Market, primarily known for its innovative products tailored to meet the evolving needs of vascular surgeons and interventional radiologists.  The company emphasizes quality and safety in its medical devices, which has resonated well with practitioners in the region. Leveraging its strong research and development capabilities, CeloNova BioSciences focuses on developing advanced embolic materials designed for effective vascular occlusion. The company’s localized support services and educational initiatives further enhance its appeal, positioning it as a trusted partner for healthcare providers in China. This attention to quality, combined with an innovative approach, has significantly boosted CeloNova's presence in the competitive landscape of the market.AngioDynamics holds a prominent position in the China Vascular Embolization Market, recognized for its comprehensive portfolio of products and services tailored to meet the needs of vascular interventional procedures.  The company offers a range of embolization devices, including products specifically designed for various vascular occlusions, catering to the dynamic needs of healthcare professionals in the region. AngioDynamics' strengths lie in its established reputation for quality, coupled with a robust distribution network that enhances its market presence. Recent strategic mergers and acquisitions have enabled AngioDynamics to expand its product offerings and enhance its technological capabilities in China. The company's commitment to innovation and healthcare partnerships effectively positions it to leverage the growing demand for vascular treatment solutions, solidifying its competitive advantage in this evolving market landscape. ### **Key Companies in the China Vascular Embolization Market Include:** ## **China Vascular Embolization Market Industry Developments** In recent months, the China Vascular Embolization Market has witnessed significant developments, particularly in the form of increased investments and technological advancements. Companies such as CeloNova BioSciences and AngioDynamics are focusing on expanding their product lines and enhancing their operational capabilities in the region. For instance, Stryker and Medtronic have been actively introducing advanced embolization devices tailored to meet the growing demand in China.  Furthermore, in August 2023, B. Braun Melsungen announced an initiative to elevate its research in interventional medicine, which may influence market dynamics positively. Current affairs, such as the ongoing focus on improving healthcare infrastructure and increasing patient access to innovative treatments, are driving market growth. The notable rise in medical tourism in China also plays a pivotal role in boosting the demand for vascular embolization procedures. However, it is essential to highlight that no recent mergers or acquisitions involving the mentioned companies have been reported within this timeframe. Overall, the increasing prevalence of vascular diseases and proactive government policies in healthcare are shaping the landscape of the China Vascular Embolization Market. ## **China Vascular Embolization Market Segmentation Insights** ### **Vascular Embolization Market Embolization Technique****Outlook** ### **Vascular Embolization Market Application****Outlook** ## Market Drivers ### Rising Healthcare Expenditure The increase in healthcare expenditure in China is a significant driver for the vascular embolization market. As the country continues to develop economically, both public and private healthcare spending has seen a marked rise. In recent years, healthcare expenditure has grown at an annual rate of approximately 10%, reflecting the government's commitment to improving health services. This increase allows for the procurement of advanced medical technologies, including those used in vascular embolization procedures. Enhanced funding enables hospitals to offer state-of-the-art treatments, which are crucial for addressing the growing burden of vascular diseases. Consequently, the vascular embolization market is likely to benefit from this upward trend in healthcare investment, as more facilities adopt these innovative procedures to meet patient needs. ### Government Initiatives and Funding Government support plays a pivotal role in the development of the vascular embolization market in China. Various initiatives aimed at improving healthcare infrastructure and access to advanced medical technologies are being implemented. The Chinese government has allocated substantial funding to enhance medical services, particularly in underserved regions. This funding is directed towards the adoption of innovative medical technologies, including embolization devices and techniques. As a result, hospitals and clinics are more likely to invest in these advanced solutions, which could lead to a notable increase in the utilization of vascular embolization procedures. Additionally, public health campaigns aimed at educating the population about vascular health may further stimulate demand for these services, thereby positively impacting the vascular embolization market. ### Growing Awareness and Patient Education The increasing awareness of vascular health among the Chinese population is a notable driver for the vascular embolization market. Educational initiatives aimed at informing patients about vascular diseases and available treatment options are gaining traction. Healthcare providers and organizations are actively promoting awareness campaigns that highlight the benefits of minimally invasive procedures, including embolization. As patients become more informed about their health and treatment choices, they are more likely to seek out advanced medical interventions. This shift in patient behavior is expected to lead to a higher demand for vascular embolization procedures. Furthermore, as the population ages and the prevalence of vascular conditions rises, the emphasis on patient education will likely continue to grow, further supporting the expansion of the vascular embolization market. ### Growing Prevalence of Vascular Diseases The rising incidence of vascular diseases in China is a critical driver for the vascular embolization market. Conditions such as aneurysms, arteriovenous malformations, and peripheral vascular diseases are becoming increasingly common, largely due to lifestyle changes and an aging population. According to recent health statistics, vascular diseases account for a significant portion of morbidity and mortality in the country. This trend necessitates advanced treatment options, including embolization procedures, which are less invasive and offer quicker recovery times. As healthcare providers seek effective solutions to manage these conditions, the demand for embolization techniques is expected to rise, thereby propelling the growth of the vascular embolization market. Furthermore, the increasing awareness among patients regarding treatment options is likely to contribute to market expansion. ### Advancements in Medical Imaging Technologies Innovations in medical imaging technologies are transforming the landscape of the vascular embolization market. Enhanced imaging modalities, such as 3D angiography and intravascular ultrasound, provide clinicians with superior visualization of vascular structures. These advancements facilitate more accurate diagnoses and treatment planning, which are essential for successful embolization procedures. In China, the integration of these technologies into clinical practice is becoming increasingly prevalent, as healthcare providers recognize their potential to improve patient outcomes. The ability to perform precise embolization procedures with real-time imaging guidance is likely to drive demand for these services. As imaging technologies continue to evolve, they will play a crucial role in shaping the future of the vascular embolization market, potentially leading to increased adoption rates among healthcare professionals. ## Future Outlook The [Vascular Embolization Market](https://www.marketresearchfuture.com/reports/vascular-embolization-market-11872) in China is projected to grow at a 9.9% CAGR from 2025 to 2035, driven by technological advancements and increasing healthcare expenditure. **New opportunities:** - Development of biodegradable embolic agents for enhanced patient safety. - Expansion of telemedicine platforms for remote embolization consultations. - Investment in AI-driven imaging technologies to improve procedural accuracy. By 2035, the vascular embolization market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Technique: Coiling Devices (Largest) vs. Non-coiling Devices (Fastest-Growing) Coiling devices hold the majority share in the China vascular embolization market due to their effectiveness and widespread adoption among medical professionals. Non-coiling devices, while currently smaller in market share, are gaining traction in specific applications, thereby indicating a shift in clinician preferences as new technologies emerge. The growth trends for coiling devices are driven by advances in technology, leading to improved performance and patient outcomes. In contrast, non-coiling devices are recognized as the fastest-growing segment, driven by innovations that enhance safety and efficacy. Increased awareness among healthcare providers about the benefits of these devices contributes to their expanding utilization in clinical settings. Coiling Devices (Dominant) vs. Non-coiling Devices (Emerging) Coiling devices are characterized by their reliability and effectiveness in occluding blood vessels, making them a staple in vascular embolization procedures. These devices benefit from established clinical protocols and extensive research backing their use, allowing for greater clinician confidence. On the other hand, non-coiling devices are emerging as effective alternatives with unique advantages, such as minimal invasiveness and flexibility in complex cases. Their growth is fostered by continuous innovation and increased investment in research and development, with manufacturers focusing on enhancing the functionality and applicability of these devices in diverse medical scenarios. ### By Application: Oncology (Largest) vs. Peripheral Vascular Disease (Fastest-Growing) In the China vascular embolization market, the application segment demonstrates a diverse market share distribution with oncology holding the largest share, driven by the rising incidence of cancer and increasing acceptance of minimally invasive procedures. Peripheral vascular disease follows as a significant segment, but it is rapidly gaining traction due to a growing aging population and increased vascular-related health issues, positioning it as a dynamic area of focus. Growth trends within this segment are strongly influenced by advancements in technology and expanding healthcare access. The demand for embolization techniques is primarily fueled by increasing investments in healthcare infrastructure and rising awareness among patients regarding embolization therapies. As both oncology and peripheral vascular disease applications evolve, innovations in treatment modalities will significantly impact their market trajectories in the coming years. Oncology: Dominant vs. Peripheral Vascular Disease: Emerging Oncology, as a dominant application within the China vascular embolization market, is characterized by its substantial contribution to the overall market share, attributed to the prevalence of various cancer types and the ongoing development of cutting-edge treatment technologies. The increasing rate of diagnoses and the shift towards minimally invasive treatments continue to enhance its position. Conversely, peripheral vascular disease is emerging as a key player in this market. The increasing incidence of vascular disorders related to lifestyle factors and the aging demographic is driving growth in this area. Innovations in devices and techniques designed to treat peripheral vascular conditions are expected to redefine its role, making it a significant area for future market expansion. ## Competitive Benchmarking The vascular embolization market in China is characterized by a dynamic competitive landscape, driven by technological advancements and increasing demand for minimally invasive procedures. Key players such as Medtronic (US), Boston Scientific (US), and Terumo (JP) are strategically positioned to leverage innovation and expand their market presence. Medtronic (US) focuses on enhancing its product portfolio through continuous research and development, while Boston Scientific (US) emphasizes strategic partnerships to bolster its market reach. Terumo (JP) is actively pursuing regional expansion, particularly in underserved areas, which collectively shapes a competitive environment that is both collaborative and competitive.The market structure appears moderately fragmented, with several players vying for market share. Key business tactics include localizing manufacturing to reduce costs and optimize supply chains, which is crucial in a market where price sensitivity is prevalent. The collective influence of these major companies fosters a competitive atmosphere that encourages innovation and efficiency, ultimately benefiting healthcare providers and patients alike. In October Medtronic (US) announced the launch of a new embolization device designed to improve patient outcomes in interventional procedures. This strategic move is significant as it not only enhances Medtronic's product offerings but also reinforces its commitment to innovation in the vascular space. The introduction of this device is expected to capture a larger share of the market, particularly among healthcare providers seeking advanced solutions. In September Boston Scientific (US) entered into a partnership with a leading Chinese healthcare provider to enhance the distribution of its embolization products. This collaboration is pivotal as it allows Boston Scientific to tap into local expertise and expand its footprint in the rapidly growing Chinese market. Such strategic alliances are likely to facilitate better access to innovative technologies for healthcare professionals, thereby improving patient care. In August Terumo (JP) completed the acquisition of a local medical device company specializing in embolization technologies. This acquisition is indicative of Terumo's strategy to strengthen its market position and diversify its product range. By integrating local innovations, Terumo aims to enhance its competitive edge and respond more effectively to the specific needs of the Chinese market. As of November current trends in the vascular embolization market include a pronounced shift towards digitalization and the integration of artificial intelligence in product development. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that prioritize these aspects will be better positioned to thrive in the evolving market. ## Recent News & Developments In recent months, the China Vascular Embolization Market has witnessed significant developments, particularly in the form of increased investments and technological advancements. Companies such as CeloNova BioSciences and AngioDynamics are focusing on expanding their product lines and enhancing their operational capabilities in the region. For instance, Stryker and Medtronic have been actively introducing advanced embolization devices tailored to meet the growing demand in China.  Furthermore, in August 2023, B. Braun Melsungen announced an initiative to elevate its research in interventional medicine, which may influence market dynamics positively. Current affairs, such as the ongoing focus on improving healthcare infrastructure and increasing patient access to innovative treatments, are driving market growth. The notable rise in medical tourism in China also plays a pivotal role in boosting the demand for vascular embolization procedures. However, it is essential to highlight that no recent mergers or acquisitions involving the mentioned companies have been reported within this timeframe. Overall, the increasing prevalence of vascular diseases and proactive government policies in healthcare are shaping the landscape of the China Vascular Embolization Market. ## Report Scope | MARKET SIZE 2024 | 208.81(USD Million) | | --- | --- | | MARKET SIZE 2025 | 229.49(USD Million) | | MARKET SIZE 2035 | 590.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.9% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Medtronic (US), Boston Scientific (US), Terumo (JP), Johnson & Johnson (US), Stryker (US), B. Braun (DE), Cook Medical (US), Abbott (US) | | Segments Covered | Technique, Application | | Key Market Opportunities | Advancements in minimally invasive techniques enhance growth potential in the vascular embolization market. | | Key Market Dynamics | Rising demand for minimally invasive procedures drives innovation in vascular embolization technologies within the region. | | Countries Covered | China | ## Frequently Asked Questions **Q: What was the market valuation of the vascular embolization market in 2024?** A: The market valuation was $208.81 Million in 2024. **Q: What is the projected market valuation for the vascular embolization market by 2035?** A: The projected market valuation for 2035 is $590.0 Million. **Q: What is the expected CAGR for the vascular embolization market during the forecast period 2025 - 2035?** A: The expected CAGR during the forecast period 2025 - 2035 is 9.9%. **Q: Which companies are considered key players in the vascular embolization market?** A: Key players include Medtronic, Boston Scientific, Terumo, Johnson & Johnson, Stryker, B. Braun, Cook Medical, and Abbott. **Q: What are the two main segments of the vascular embolization market?** A: The two main segments are Technique and Application. **Q: What was the valuation of coiling devices in the vascular embolization market in 2024?** A: The valuation of coiling devices was $83.53 Million in 2024. **Q: What is the projected valuation for non-coiling devices by 2035?** A: The projected valuation for non-coiling devices by 2035 is $356.5 Million. **Q: Which application segment had the highest valuation in 2024?** A: The Oncology application segment had the highest valuation at $60.0 Million in 2024. **Q: What is the projected valuation for the neurology application segment by 2035?** A: The projected valuation for the neurology application segment by 2035 is $140.0 Million. **Q: How does the vascular embolization market in China compare to other regions?** A: While specific comparisons to other regions are not provided, the growth trajectory suggests a robust development in the China vascular embolization market. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-vascular-embolization-market-52060*